Women with advanced ovarian cancer who begin treatment with olaparib are more likely to respond to the drug if it has been more than a year since their last round of chemotherapy, according to new research.

A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumours in half of women with the disease.

An experimental cancer drug which targets cancer cells’ DNA repair could be an effective treatment for a range of cancers, the first clinical trial in patients has shown.